Takeda Pharmaceutical stock after-hours at EUR 16.55: quote at 8:08 p.m. CEST from Lang & Schwarz
Published on 10/07/2026 at 20:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Takeda Pharmaceutical stock was at EUR 16.55 after-hours at 8:08 p.m. CEST on October 7, 2026, at Lang & Schwarz. The bid was EUR 16.00 and the ask EUR 17.10.
Trading in Frankfurt
The after-hours price was recorded after the Xetra session. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.
Recent pipeline developments
In a September 30, 2026, release, Takeda reported Phase 3 LATITUDE results for investigational zasocitinib in adults with moderate-to-severe plaque psoriasis. In the head-to-head LATITUDE Atlas study, 36.5 percent of patients receiving zasocitinib achieved complete skin clearance at week 16, compared with 13.9 percent for deucravacitinib.
In a September 22, 2026, release, Takeda said it plans to present oncology pipeline data at the ESMO Congress in Madrid from October 23 through October 27. The planned program includes late-breaking Phase 3 data for arcotatug tavatecan in previously treated advanced gastric cancer and presentations on TAK-928 in non-small cell lung cancer.
Takeda identified arcotatug tavatecan and TAK-928 as investigational compounds that have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
